Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06989437 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
A Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Cachexia, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 982
- Enrollment target
- 20
- Study locations
NCT06989437: Recruiting Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Cachexia, sponsored by Pfizer.
NCT06989437 is a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Cachexia that is actively recruiting participants, run by Pfizer. The registered enrollment target is 982 participants, above the 135-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (627% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06989437, a Phase 2 study of Metastatic Pancreatic Ductal Adenocarcinoma and Cachexia, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 982 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ponsegromab
Study Locations (20)
Arkansas
- Central Arkansas Radiation Therapy Institute, dba CARTI - Bryant
- Central Arkansas Radiation Therapy Institute, dba CARTI - Conway
- CARTI Cancer Center - Little Rock
- Central Arkansas Radiation Therapy Institute, dba CARTI - North Little Rock
- Central Arkansas Radiation Therapy Institute, dba CARTI - Pine Bluff
Hawaii
- Invision, LLC - Honolulu
- University of Hawaii Cancer Center - Honolulu
- Cardiology Associates, Inc - ‘Aiea
Nevada
- Renown Health Medical Oncology - Reno
- Renown Office of Clinical Research - Reno
- Renown Regional Medical Center - Reno
Oregon
- OHSU Center for Health & Healing 1 - Portland
- Oregon Health and Science University - Portland
- OSHU Center for Health and Healing 2 - Portland
California
- Cedars-Sinai Cancer at Cedars-Sinai Medical Center - Los Angeles
- Providence Medical Foundation - Santa Rosa
Illinois
- Hope and Healing Cancer Services - Hinsdale
- Hope and Healing Cancer Services New Lenox - New Lenox
Washington
- Virginia Mason Medical Center - Seattle
New South Wales
- Shoalhaven District Memorial Hospital - Nowra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 982 participants |
| Start Date | 2025-10-03 |
| Est. Completion | 2029-12-10 |
| Phase | Phase 2 |
What NCT06989437 shows while recruiting
NCT06989437 is an interventional study that assigns participants to a tested intervention. The registered 982 participants enrollment target is mid-sized for trials with a published cap, above the 135-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (627% higher).
The record links to 2 conditions, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT06989437 names 20 study sites across 8 states, led by Arkansas, Hawaii, Nevada.
Frequently Asked Questions
What is clinical trial NCT06989437 about?
NCT06989437 is a clinical study titled "A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue". Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.
What is the current status of trial NCT06989437?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 982 participants. The study started on 2025-10-03. Estimated completion is 2029-12-10.
What conditions does trial NCT06989437 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Cachexia.
What interventions are being tested in trial NCT06989437?
The interventions under investigation include: placebo (DRUG), ponsegromab (DRUG).
Who is sponsoring clinical trial NCT06989437?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06989437 being conducted?
This trial has 20 study locations across Arkansas, California, Hawaii, Illinois, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06989437's enrollment target sits among peer trials
982 2nd of 20 the highest of 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Pancreatic Ductal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
RECRUITING · Phase 2
-
Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy
ACTIVE NOT RECRUITING · Phase 2
-
BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959095 · 981 participants · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI